A translational journey into resistance: decoding the role of NF1 in CDK4/6-inhibitor failure.
作者信息
Schettini Francesco, Bergamino Milana
机构信息
Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain; Department of Medical Oncology, Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain; Department of Medical Oncology, Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain.
出版信息
EBioMedicine. 2025 Jul 17;118:105860. doi: 10.1016/j.ebiom.2025.105860.
Abstract
摘要
相似文献
1
A translational journey into resistance: decoding the role of NF1 in CDK4/6-inhibitor failure.耐药性的转化之旅：解读NF1在CDK4/6抑制剂失效中的作用
EBioMedicine. 2025 Jul 17;118:105860. doi: 10.1016/j.ebiom.2025.105860.
2
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer.激素受体阳性转移性乳腺癌中NF1改变与CDK4/6抑制剂耐药性的床旁到实验室的转化分析
EBioMedicine. 2025 Jun 26;118:105828. doi: 10.1016/j.ebiom.2025.105828.
3
Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.MEK与CDK4/6抑制剂联合在KRAS突变型结直肠癌模型中的体内外疗效。
Oncotarget. 2016 Jun 28;7(26):39595-39608. doi: 10.18632/oncotarget.9153.
4
Dual Inhibition of CDK4/6 and mTORC1 Establishes a Preclinical Strategy for Translocation Renal Cell Carcinoma.CDK4/6和mTORC1的双重抑制为易位性肾细胞癌确立了一种临床前策略。
bioRxiv. 2025 Jul 17:2025.07.11.663903. doi: 10.1101/2025.07.11.663903.
5
Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.抑制自噬作为1型神经纤维瘤病肿瘤的一种新疗法。
Mol Oncol. 2025 Mar;19(3):825-851. doi: 10.1002/1878-0261.13704. Epub 2024 Aug 11.
6
Stabilization of RUNX1 Induced by O-GlcNAcylation Promotes PDGF-BB-Mediated Resistance to CDK4/6 Inhibitors in Breast Cancer.O-连接的N-乙酰葡糖胺糖基化诱导的RUNX1稳定促进血小板衍生生长因子BB介导的乳腺癌对CDK4/6抑制剂的抗性。
Cancer Res. 2025 May 2;85(9):1708-1724. doi: 10.1158/0008-5472.CAN-24-2492.
7
The NF1 gene mutations and co-mutations in lung adenocarcinomas with brain metastasis.伴有脑转移的肺腺癌中的NF1基因突变和共突变。
Indian J Pathol Microbiol. 2024 Sep 14. doi: 10.4103/ijpm.ijpm_424_24.
8
Bone mineral density, vitamin D and osseous metabolism indices in neurofibromatosis type 1: A systematic review and meta-analysis.1 型神经纤维瘤病患者的骨密度、维生素 D 和骨代谢指标：系统评价和荟萃分析。
Bone. 2024 Mar;180:116992. doi: 10.1016/j.bone.2023.116992. Epub 2023 Dec 21.
9
Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study.HER2低表达对HR阳性/HER2阴性转移性乳腺癌内分泌治疗联合或不联合CDK4/6抑制剂疗效的影响：一项前瞻性研究。
Thorac Cancer. 2024 Apr;15(12):965-973. doi: 10.1111/1759-7714.15282. Epub 2024 Mar 13.
10
Understanding and overcoming CDK4/6 inhibitor resistance in HR+/HER2- metastatic breast cancer: clinical and molecular perspectives.了解并克服激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌中CDK4/6抑制剂耐药性：临床与分子视角
Ther Adv Med Oncol. 2025 Jul 10;17:17588359251353623. doi: 10.1177/17588359251353623. eCollection 2025.
本文引用的文献
1
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer.激素受体阳性转移性乳腺癌中NF1改变与CDK4/6抑制剂耐药性的床旁到实验室的转化分析
EBioMedicine. 2025 Jun 26;118:105828. doi: 10.1016/j.ebiom.2025.105828.
2
Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies.克服激素受体阳性、人表皮生长因子受体2阴性乳腺癌对细胞周期蛋白依赖性激酶4/6抑制剂的耐药性：创新联合疗法与新兴策略
Cancer Treat Rev. 2025 Sep;139:102980. doi: 10.1016/j.ctrv.2025.102980. Epub 2025 Jun 14.
3
Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study.确定激素受体阳性/人表皮生长因子受体2阴性乳腺癌中新辅助化疗和内分泌治疗的治疗反应预测指标及诱导的分子变化：NEOENDO转化研究
ESMO Open. 2024 Dec;9(12):103989. doi: 10.1016/j.esmoop.2024.103989. Epub 2024 Nov 27.
4
Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.Elacestrant 在 ER+/HER2- 转移性乳腺癌伴 ESR1 突变肿瘤中的应用：III 期 EMERALD 试验中根据内分泌治疗联合 CDK4/6 抑制剂治疗持续时间的亚组分析及临床亚组分析。
Clin Cancer Res. 2024 Oct 1;30(19):4299-4309. doi: 10.1158/1078-0432.CCR-24-1073.
5
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial.CDK4/6抑制剂与化疗用于晚期激素受体阳性/人表皮生长因子受体2阴性乳腺癌的疗效比较：KENDO随机II期试验结果及相关生物标志物分析
Oncologist. 2024 May 3;29(5):e622-e634. doi: 10.1093/oncolo/oyad337.
6
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.阿贝西利单药或联合内分泌治疗晚期乳腺癌患者循环肿瘤 DNA 中基线和获得性基因组改变的图谱。
Clin Cancer Res. 2024 May 15;30(10):2233-2244. doi: 10.1158/1078-0432.CCR-22-3573.
7
Faecal microbiota composition is related to response to CDK4/6-inhibitors in metastatic breast cancer: A prospective cross-sectional exploratory study.粪便微生物组成与转移性乳腺癌对 CDK4/6 抑制剂的反应相关：一项前瞻性横断面探索性研究。
Eur J Cancer. 2023 Sep;191:112948. doi: 10.1016/j.ejca.2023.112948. Epub 2023 Jun 20.
8
Inactivating Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.失活突变在晚期乳腺癌中富集，并导致内分泌治疗耐药。
Clin Cancer Res. 2020 Feb 1;26(3):608-622. doi: 10.1158/1078-0432.CCR-18-4044. Epub 2019 Oct 7.
9
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.针对乳腺癌治疗中的 PI3K/AKT/mTOR 和 Raf/MEK/ERK 通路。
Cancer Treat Rev. 2013 Dec;39(8):935-46. doi: 10.1016/j.ctrv.2013.03.009. Epub 2013 May 3.
Zotero 插件